Ovarian Cancer Market

Market Overview:

The global ovarian cancer market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.59% during 2025-2033. North America leads the market attributed to its advanced healthcare infrastructure, strong research capabilities, and high demand for innovative treatment options. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The development of targeted treatments, immune therapies, and individualized medicine is broadening therapeutic choices. These therapies are more efficient and less harmful than conventional chemotherapy, enhancing patient results. Moreover, advancements in clinical trials are fostering innovation, encouraging new treatments that provide optimism for improved survival rates and enhanced quality of life for patients. Besides this, collaborative partnerships among pharmaceutical firms, research organizations, and non-profit entities are driving advancements in ovarian cancer therapies. These collaborations improve drug development, clinical trials, and awareness initiatives by combining resources and expertise. Teamwork accelerates the translation of research into effective treatments and enhances the overall market outlook for ovarian cancer treatment. Furthermore, the growing awareness about ovarian cancer is leading to earlier diagnosis, which is essential for enhancing survival rates. Health campaigns and advocacy organizations are informing individuals about symptoms and risk elements, encouraging more women to pursue medical consultation. Timely detection via enhanced screening methods boosts the efficacy of current therapies.

Ovarian Cancer Market Trends:

Increased Healthcare Investments and Government Initiatives

Governments around the globe, are becoming more aware about the increasing impact of cancer, are directing additional resources towards research, treatment initiatives, and the advancement of innovative medical technologies. These investments facilitate the discovery of novel therapeutic strategies, improved diagnostic instruments, and refined treatment methodologies for ovarian cancer. In addition, partnerships among pharmaceutical companies, biotech organizations, and academic institutions are speeding up the identification of new treatments. These collaborations result in the creation of more focused, individualized, and efficient treatment alternatives. Apart from this, the heightened financial backing promotes the growth of clinical trials and the swift commercialization of innovative therapies. This collaborative endeavor boosts patient care, increases survival rates, and guarantees that additional resources are accessible for ongoing research, ultimately contributing to the growth of the ovarian cancer market and enhancing patient outcomes.

Approval of Targeted Therapies and New Treatment Standards

The introduction of targeted therapies and the creation of new treatment benchmarks for particular ovarian cancer subtypes are bolstering the market growth. Progress in comprehending the genetic and molecular foundations of ovarian cancer is resulting in the creation of therapies that focus on particular mutations, providing patients with more effective treatment choices. With new therapies showing encouraging effectiveness in clinical trials and receiving regulatory approval, they offer more tailored and accurate care, enhancing patient outcomes. This advancement in targeted therapies is increasing survival rates while also generating higher demand for specialized treatments, driving further growth and investment in the ovarian cancer industry. In May 2025, the FDA approved Verastem Oncology’s drug combination for low-grade serous ovarian cancer (LGSOC) driven by KRAS mutations, marking the first treatment for this rare cancer. The combination of avutometinib and defactinib showed a 44% response rate in a Phase 2 study. This approval sets the therapy as the new standard of care for recurrent LGSOC with KRAS mutations.

Advancements in Research and Treatment Options

The continuous advancement of innovative therapies is significantly driving the growth of the ovarian cancer market by improving treatment efficacy and patient outcomes. Advances in targeted treatments, immunotherapy, and personalized medicine offer patients more customized and effective options for therapy. These developments enhance survival rates and treatment effectiveness, contributing to the market growth. Besides this, studies on biomarkers and genetic profiling are resulting in more targeted and timely treatments, which consequently enhances market engagement and funding in ovarian cancer therapies. In 2025, Tilt Biotherapeutics raised €22.6 million ($25.6 million) in Series B funding to advance its oncolytic virus therapy, TILT-123, into a Phase II trial for platinum-resistant ovarian cancer (PROC). The therapy, combined with T cell-based treatments like Merck's Keytruda, showed promising early results, with 64% of patients achieving disease control.

Ovarian Cancer Market Growth Drivers:

Expansion of Comprehensive Cancer Screening Programs

The expansion of thorough cancer screening initiatives is a major factor influencing the ovarian cancer market. These initiatives focus on identifying cancer during its initial phases, allowing for more successful therapies and better patient results. Through the integration of gender-specific diagnostics, hereditary cancer risk assessment, and tumor markers, these initiatives offer a thorough strategy for cancer detection. As knowledge about the significance of early detection expands, the need for accessible and cost-effective screening options rises, especially in areas with increasing cancer rates. This broader access to screening services not only facilitates earlier intervention but also expands the market for diagnostic tools, driving the demand for innovative products and services in the ovarian cancer space. In 2025, Metropolis Healthcare launched the TruHealth Cancer Screen 360, a comprehensive cancer screening panel aimed at improving early cancer detection in India. The panel includes gender-specific diagnostics, hereditary cancer risk analysis, and tumor markers for multiple cancers. This initiative seeks to address the rising cancer burden, especially in urban and non-urban areas, by making screening more accessible and affordable.

Rise of Genetic Testing and Risk Assessment Initiatives

Enhanced emphasis on identifying individuals with greater genetic susceptibility allows for earlier identification and tailored prevention approaches. This transition towards proactive healthcare enables focused interventions, resulting in better outcomes and possibly lower incidence rates. With genetic testing becoming increasingly available, especially for at-risk individuals and their families, the need for associated diagnostic services, treatments, and educational resources grows. Moreover, these efforts enable patients to make knowledgeable choices regarding their health, ultimately supporting the market growth through heightened awareness and access to early detection tools. In 2024, Stanford Medicine received a $3.5 million legacy gift from Bright Pink to launch the Bright Pink Preventive Risk Outreach and Cascade Testing (PROACT) Program. The initiative aimed to increase genetic testing for breast and ovarian cancer, focusing on at-risk individuals and their families. The program builds on Bright Pink’s previous work, making genetic risk assessments more accessible and empowering proactive health management.

Advancements in AI-Driven Cancer Research

The incorporation of artificial intelligence (AI) into ovarian cancer studies is propelling market growth by enhancing early detection, personalized treatment strategies, and accelerating research advancements. AI technologies allow for the examination of large datasets, revealing patterns and insights that were once challenging to discover. Utilizing machine learning (ML) algorithms on patient data enables researchers to create more precise diagnostic tools, enhance treatment protocols, and anticipate patient outcomes. As AI continues to transform research methodologies, it enhances the effectiveness of treatments and improves survival rates, thereby increasing the demand for innovative cancer care solutions and further supporting the market growth. In 2025, the Global Ovarian Cancer Research Consortium launched a $1 million AI Accelerator Grant in partnership with Microsoft's AI for Good Lab. The initiative aims to advance ovarian cancer research by using AI to improve survival rates. The grant will fund multi-country, multidisciplinary research teams to tackle the global ovarian cancer crisis.

Ovarian Cancer Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global ovarian cancer market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on type, treatment type and end user.

Breakup by Type:

• Epithelial Ovarian Cancer
• Germ Cell Ovarian Cancer
• Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

The report has provided a detailed breakup and analysis of the market based on the type. This includes epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. According to the report, epithelial ovarian cancer represented the largest segment.

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

• Immunotherapy
• Chemotherapy
• Targeted Therapy
• Surgery
• Others

Immunotherapy is the most popular treatment type

A detailed breakup and analysis of the market based on the treatment type has also been provided in the report. This includes lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. According to the report, lateral flow assays hold the largest market share.

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

• Hospitals
• Homecare
• Speciality Centre
• Others

The report has provided a detailed breakup and analysis of the market based on end user. This includes hospitals, homecare, speciality centre, and others.

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

Competitive Landscape:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• AbbVie Inc.
• Amneal Pharmaceuticals Inc.
• AstraZeneca plc
• Eli Lilly and Company
• F. Hoffmann-La
• Roche AG
• GSK plc
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Recent Developments:

• In September 2025, Wrapped in Love collaborated with Kelly Ripa to launch limited-edition teal socks for Ovarian Cancer Awareness Month. The socks, designed to honor personal losses to ovarian cancer, feature a teal ribbon and heart design. Priced at $20 per pair, 100% of proceeds will go to the Ovarian Cancer Research Alliance (OCRA) to support cancer research.
• In August 2025, GSK entered the oncology segment in India with the launch of Jemperli (dostarlimab) and Zejula (niraparib) for the treatment of gynaecological cancers. These therapies address a significant unmet need in women's cancer care, particularly for endometrial and ovarian cancers. GSK's commitment to expanding its specialty medicine portfolio in India is underscored by the launch, as the incidence of these cancers is projected to rise significantly by 2045.
• In July 2025, Apollo Cancer Centre and Apollo Proton Cancer Centre launched "End-O Check," an early detection program for ovarian and endometrial cancers, targeting postmenopausal women and high-risk groups. The initiative combines risk assessments, symptom evaluation, and diagnostic testing to promote early diagnosis and timely intervention.
• In May 2025, the World Ovarian Cancer Coalition launched the Global Expert Advisory Group on Ovarian Cancer to elevate ovarian cancer as a global health priority. The group will focus on raising awareness, optimizing diagnosis, and improving access to services, especially for hereditary ovarian cancer. It aims to reduce global ovarian cancer mortality and ensure better survival rates and quality of life for women worldwide.
• In April 2025, the FDA approved a ready-to-dilute, multi-dose vial of thiotepa (Tepylute) for the treatment of breast and ovarian cancer. This new formulation simplifies preparation, enhances flexibility, and reduces errors, offering consistent dosing accuracy. Tepylute, available in 15 mg and 100 mg vials, is stable for 14 days after opening.
• In February 2025, Jaggad partnered with the Ovarian Cancer Research Foundation (OCRF) to launch a special two-piece collection, with 100% of the proceeds supporting ovarian cancer research. The collection includes the OCRF Boxy Tee and Turquoise Bay Sweater, available online during Ovarian Cancer Awareness Month.
• In September 2022, AstraZeneca and Merck jointly declared that Lynparza (olaparib) had received approval in China for the maintenance treatment of adult patients diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval applies specifically to patients who have shown a complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.
• In September 2022, Pfizer and Strata Oncology announced an expansion of their partnership to include a clinical trial that will evaluate multiple cancer therapies in novel, biomarker-guided patient cohorts.
• Tesaro, which is now part of GlaxoSmithKline (GSK), launched "Zejula" (niraparib), another PARP inhibitor, for the treatment of ovarian cancer. Zejula is indicated for maintenance treatment in women with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Ovarian Cancer Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the ovarian cancer market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global ovarian cancer market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the ovarian cancer industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.